ChromaDex (CDXC) News Today → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free CDXC Stock Alerts $3.16 -0.14 (-4.24%) (As of 05/20/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | americanbankingnews.comChromaDex Co. Expected to Post Q4 2024 Earnings of $0.00 Per Share (NASDAQ:CDXC)May 13, 2024 | americanbankingnews.comChromaDex Co. (NASDAQ:CDXC) to Post Q2 2024 Earnings of ($0.03) Per Share, Roth Capital ForecastsMay 13, 2024 | americanbankingnews.comChromaDex (NASDAQ:CDXC) Receives Buy Rating from HC WainwrightMay 11, 2024 | americanbankingnews.comRoth Capital Comments on ChromaDex Co.'s Q1 2025 Earnings (NASDAQ:CDXC)May 10, 2024 | finance.yahoo.comChromaDex Corp (CDXC) Q1 2024 Earnings: Aligns with EPS Projections, Misses Revenue EstimatesMay 10, 2024 | marketbeat.comChromaDex Co. (NASDAQ:CDXC) Expected to Earn Q1 2025 Earnings of $0.00 Per ShareChromaDex Co. (NASDAQ:CDXC - Free Report) - Analysts at Roth Capital decreased their Q1 2025 earnings estimates for shares of ChromaDex in a report issued on Thursday, May 9th. Roth Capital analyst S. Mcgowan now expects that the company will post earnings per share of $0.00 for the quarter, downMay 9, 2024 | markets.businessinsider.comChromadex Poised for Continued Growth; Selvaraju Reiterates Buy Rating with $6 TargetMay 9, 2024 | finance.yahoo.comChromaDex Corporation (NASDAQ:CDXC) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comChromaDex Corp (CDXC) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...May 9, 2024 | marketbeat.comChromaDex's (CDXC) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $6.00 target price on shares of ChromaDex in a research report on Thursday.May 8, 2024 | investorplace.comCDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | msn.comChromaDex GAAP EPS of -$0.01 in-line, revenue of $22.2M misses by $1.41MMay 8, 2024 | finance.yahoo.comChromaDex Corporation Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comChromaDex is about to announce its earnings — here's what to expectMay 6, 2024 | finance.yahoo.comAn Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 43% UndervaluedMay 1, 2024 | marketbeat.comChromaDex Co. (NASDAQ:CDXC) Short Interest UpdateChromaDex Co. (NASDAQ:CDXC - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,480,000 shares, an increase of 12.1% from the March 31st total of 1,320,000 shares. Approximately 3.3% of the company's shares are sold short. Based on an average daily volume of 309,600 shares, the short-interest ratio is presently 4.8 days.May 1, 2024 | finance.yahoo.comChromaDex Corporation (CDXC)May 1, 2024 | marketbeat.comChromaDex (CDXC) Set to Announce Quarterly Earnings on WednesdayChromaDex (NASDAQ:CDXC) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=588558)April 30, 2024 | finance.yahoo.comChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy SupplementApril 30, 2024 | businesswire.comChromaDex's NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy SupplementApril 25, 2024 | businesswire.comChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®April 24, 2024 | businesswire.comChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024April 23, 2024 | businesswire.comChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers MarketApril 17, 2024 | msn.comChromaDex (CDXC) Price Target Increased by 9.92% to 6.60April 14, 2024 | marketbeat.comShort Interest in ChromaDex Co. (NASDAQ:CDXC) Grows By 12.8%ChromaDex Co. (NASDAQ:CDXC - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,320,000 shares, an increase of 12.8% from the March 15th total of 1,170,000 shares. Approximately 3.0% of the shares of the company are short sold. Based on an average daily trading volume, of 259,700 shares, the short-interest ratio is presently 5.1 days.April 9, 2024 | marketbeat.comChromaDex (NASDAQ:CDXC) PT Raised to $6.00Roth Mkm upped their price target on ChromaDex from $4.25 to $6.00 and gave the company a "buy" rating in a report on Tuesday.March 27, 2024 | stocknews.com3 Chemical Stocks Poised for GainsMarch 26, 2024 | businesswire.comChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency ProgramMarch 19, 2024 | marketbeat.comShort Interest in ChromaDex Co. (NASDAQ:CDXC) Declines By 9.0%ChromaDex Co. (NASDAQ:CDXC - Get Free Report) saw a significant decline in short interest in the month of February. As of February 29th, there was short interest totalling 1,210,000 shares, a decline of 9.0% from the February 14th total of 1,330,000 shares. Based on an average daily volume of 81,100 shares, the short-interest ratio is currently 14.9 days. Currently, 2.7% of the shares of the company are sold short.March 14, 2024 | marketbeat.comEquities Analysts Offer Predictions for ChromaDex Co.'s FY2025 Earnings (NASDAQ:CDXC)ChromaDex Co. (NASDAQ:CDXC - Free Report) - Analysts at HC Wainwright issued their FY2025 earnings estimates for ChromaDex in a research note issued to investors on Monday, March 11th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn $0.07 per share for the year. The consenMarch 8, 2024 | finance.yahoo.comChromaDex Full Year 2023 Earnings: EPS Beats ExpectationsMarch 8, 2024 | marketbeat.comChromaDex Co. Forecasted to Earn Q1 2025 Earnings of $0.01 Per Share (NASDAQ:CDXC)ChromaDex Co. (NASDAQ:CDXC - Free Report) - Investment analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of ChromaDex in a report issued on Thursday, March 7th. Roth Capital analyst S. Mcgowan anticipates that the company will earn $0.01 per share for the quarter. The consensMarch 8, 2024 | uk.sports.yahoo.comPersona 3 Reload is getting the DLC it needs, but not the one it deservesMarch 7, 2024 | finance.yahoo.comChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDAMarch 6, 2024 | markets.businessinsider.comWhat Wall Street expects from ChromaDex's earningsMarch 6, 2024 | investorplace.comCDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023March 6, 2024 | benzinga.comEarnings Preview For ChromaDexMarch 6, 2024 | finance.yahoo.comChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 ResultsMarch 2, 2024 | finance.yahoo.comInsiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the companyFebruary 21, 2024 | finance.yahoo.comChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024February 21, 2024 | businesswire.comChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024February 6, 2024 | entrepreneur.comTop 3 Accelerating Chemical Stocks to ConsiderFebruary 5, 2024 | finance.yahoo.comChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024January 26, 2024 | finance.yahoo.comChromaDex to Present at the Lytham Partners 2024 Investor Select ConferenceJanuary 24, 2024 | seekingalpha.comChromaDex: Growth At A Reasonable PriceJanuary 19, 2024 | finance.yahoo.comChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To ProfitDecember 29, 2023 | marketbeat.comChromaDex (NASDAQ:CDXC) Upgraded at StockNews.comStockNews.com upgraded ChromaDex from a "buy" rating to a "strong-buy" rating in a research report on Friday.December 20, 2023 | businesswire.comChromaDex Supports the US Military with its Industry Leading NAD + Supplement, Tru NiagenDecember 20, 2023 | baystreet.caChromaDex Flat on Assistance to Military Get ChromaDex News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter. Email Address Read this before you buy AI stocks (Ad)BREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts. Starting today, you could siphon a new stream of income from this $3 billion pool of cash. CDXC Media Mentions By Week CDXC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDXC News Sentiment▼-0.300.42▲Average Medical News Sentiment CDXC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDXC Articles This Week▼42▲CDXC Articles Average Week Get ChromaDex News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ACB News Today MDWD News Today FTLF News Today BTMD News Today NAII News Today MTEX News Today MNMD News Today USNA News Today CGC News Today MGNX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDXC) was last updated on 5/20/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsNext President (Not Trump. Not Biden.)The Freeport Society**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock Digest Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChromaDex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
